Pfizer gears up for migraine battle

Posted 17 May 2022 AM

Pfizer's enthusiasm to become a big player in the CGRP migraine market means increased choice for migraine sufferers in Australia may come sooner than expected.

The recent announcement that Pfizer would buy Biohaven for US$11.6 billion (AU$16.9 billion) follows a deal last November that gave Pfizer a 2.6 per cent stake in Biohaven and distribution rights for migraine treatment Nurtec outside of the United States.

To see the whole article, please login